TARO Stock Cash Flow Statements

Taro Pharmaceutical Industries Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Taro Pharmaceutical Industries Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2012-03-31

cash flows from operating activities:
net income	23,316,000	-18,767,000	-28,882,000	33,036,000	45,062,000	-449,956,000	54,421,000	67,678,000	56,210,000	66,241,000	62,548,000	67,428,000	-13,567,000	16,614,000	52,482,000	54,555,000	82,962,000	139,911,000	123,900,000	109,893,000	47,403,000
adjustments required to reconcile net income to net cash from operating activities:
depreciation and amortization	6,449,000	6,346,000	6,343,000	5,976,000	5,790,000	5,571,000	5,282,000	5,447,000	5,583,000	5,071,000	4,516,000	4,299,000	2,758,000	4,228,000	4,019,000	3,775,000	3,762,000	3,670,000	3,705,000	3,692,000	4,598,000
realized loss on sale of long-lived assets
change in derivative instruments	-148,000	-166,000	154,000	552,000	-19,000	-923,000	746,000	-637,000	-337,000	-2,421,000	-1,020,000	3,546,000	-6,774,000	-253,000	-1,295,000	-3,093,000	-3,067,000	2,164,000	-334,000	2,671,000	-3,392,000
effect of exchange differences on intercompany balances
foreign exchange effect of marketable securities and bank deposits
adjustments to opening balance sheet
deferred income taxes	5,683,000	11,244,000	-6,536,000	7,714,000	-37,224,000	-2,367,000	9,660,000	-2,378,000	-2,628,000	2,930,000	-3,280,000	1,575,000	55,266,000	45,727,000	10,988,000	4,825,000	86,844,000	-1,716,000	8,860,000	-20,282,000	4,075,000
decrease (increase) in trade receivables							-7,894,000			24,431,000				3,838,000	-15,404,000	18,270,000					9,879,000
increase in other receivables, prepaid expenses and other																					-535,000
increase in inventories	-68,000	-2,568,000	-10,765,000	-2,314,000	-990,000	-13,150,000	4,802,000	-9,436,000	-155,000	-205,000			4,817,000	725,000	-3,872,000	-2,114,000	5,350,000	2,491,000	-2,421,000	-9,190,000	-1,583,000
decrease (increase) in income tax receivables
increase in trade payables																					-521,000
increase in other accounts payable and accrued expenses																					3,241,000
increase in income tax payables																					12,138,000
expense from amortization of marketable securities bonds	3,108,000	2,179,000
net cash from operating activities	-52,016,000	43,993,000	51,055,000	42,862,000	-112,257,000	64,110,000	49,597,000	98,650,000	40,754,000	82,604,000	75,210,000	82,440,000	58,560,000	87,098,000	66,029,000	72,668,000	117,080,000	127,778,000	136,712,000	55,965,000	78,094,000
capex	-523,000	1,225,000	2,544,000	-957,000	106,000	1,304,000	-2,000	-521,000	-317,000	2,317,000	435,000	1,823,000	737,000	655,000	-445,000	1,180,000	338,000	0	0	0	-977,000
free cash flows	-52,539,000	45,218,000	53,599,000	41,905,000	-112,151,000	65,414,000	49,595,000	98,129,000	40,437,000	84,921,000	75,645,000	84,263,000	59,297,000	87,753,000	65,584,000	73,848,000	117,418,000	127,778,000	136,712,000	55,965,000	77,117,000
cash flows from investing activities:
purchase of property, plant and equipment																					-1,610,000
investment in other intangible assets	-35,000	-72,000	-44,000	-41,000	-13,000	-63,000	-767,000	-971,000	-15,000	-30,000	-1,049,000	-45,000	19,000		502,000	-2,056,000			-11,000	-11,000
investment in short-term bank deposits
investment in marketable securities		-12,500,000				-40,825,000			-107,424,000	-9,070,000	-51,391,000	-107,644,000									-4,909,000
proceeds from marketable securities
(investment in) proceeds from acquisitions and sale of long-lived assets
cash acquired from acquisition
net cash from investing activities	-31,526,000	-16,427,000	21,946,000	13,004,000	78,812,000	-46,021,000	-44,403,000	-123,617,000	-113,073,000	-17,069,000	115,635,000	8,263,000	-540,373,000	-6,732,000	37,225,000	-234,801,000	-41,689,000	86,539,000	-100,764,000	-61,864,000	15,586,000
cash flows from financing activities:
repurchase of treasury stock
net cash from financing activities	-6,615,000	-18,319,000	-20,953,000				-157,000				-7,749,000	-24,655,000	465,205,000	-14,504,000	-31,928,000	-8,489,000	-25,185,000	-29,094,000	-108,129,000	-132,489,000	-6,588,000
effect of exchange rate changes on cash and cash equivalents	-1,063,000	464,000	211,000	1,499,000	197,000	601,000	-1,044,000				515,000	-670,000	2,962,000	10,000	1,282,000	936,000	547,000	-1,215,000	-913,000	363,000	1,173,000
increase in cash and cash equivalents		9,711,000	52,259,000			18,690,000			-72,319,000	65,535,000	183,611,000	65,378,000					50,753,000				88,265,000
cash and cash equivalents at the beginning of the period																					150,001,000
cash and cash equivalents at the end of the period																					238,266,000
supplemental disclosure of cash flow transactions:
cash paid during the year for:
income taxes	1,199,000	3,333,000	5,208,000	3,573,000	13,477,000	7,119,000	15,763,000	16,932,000	11,409,000	10,432,000	5,151,000	36,830,000	3,564,000	2,409,000	10,588,000	29,595,000					1,039,000
cash received during the year for:
non-cash investing transactions:
purchase of property, plant and equipment included in accounts payable	-523,000	1,225,000	2,544,000	-957,000	106,000	1,304,000	-2,000	-521,000	-317,000	2,317,000	435,000	1,823,000	737,000	655,000	-445,000	1,180,000	338,000
adjustment to purchase price
investment in intangible assets on credit
non-cash financing transactions:
purchase of treasury stock	-6,615,000	-18,319,000	-20,953,000								-7,749,000	-24,655,000	-34,795,000	-14,504,000	-31,928,000	-8,489,000		-29,094,000	-108,129,000	-132,489,000
purchase of marketable securities									8,153,000	2,436,000	-2,539,000	8,629,000	1,692,000
realized losss on sale of long-lived assets
effect of change in exchange rate on marketable securities and bank deposits	993,000	-589,000
increase in trade receivables		-3,295,000									-14,627,000	-2,897,000	16,142,000					-2,126,000	39,935,000	-51,220,000
decrease (increase) in other receivables, income tax receivables, prepaid expenses and other
decrease in trade, income tax, accrued expenses and other payables
purchase of plant, property & equipment	-1,976,000	-3,855,000	-2,773,000	-5,257,000	-3,820,000	-5,133,000		-5,747,000	-5,634,000	-7,969,000	-6,057,000	-6,078,000	-7,360,000	-5,933,000	-7,252,000	-4,557,000		-7,139,000	-10,054,000	-9,184,000
proceeds from (investment in) marketable securities			24,763,000	18,302,000														15,000	0	80,000
decrease in cash and cash equivalents							3,993,000							65,872,000	72,608,000	-169,686,000			-73,094,000	-138,025,000
cash and cash equivalents at beginning of period	0	605,177,000	0	0	0	513,354,000		0	0	567,451,000	0	576,611,000	23,788,000	0	0	600,399,000		0	0	576,757,000
cash and cash equivalents at end of period	-91,220,000	614,888,000	52,259,000	54,122,000	-33,248,000	532,044,000		-51,306,000	-72,319,000	632,986,000	183,611,000	641,989,000	10,142,000	65,872,000	72,608,000	430,713,000		184,008,000	-73,094,000	438,732,000
increase in income tax receivables
(investment in) proceeds from acquisitions, net of sale of long-lived assets
decrease in trade receivables			15,288,000			45,921,000
increase in other receivables, income tax receivables, prepaid expenses and other	126,000	-2,598,000	-4,363,000	-3,511,000
increase in trade, income tax, accrued expenses and other payables	-112,193,000	52,211,000	77,287,000	-2,289,000
(investment in) proceeds from marketable securities														-116,986,000	-206,464,000	-275,128,000
realized gain on sale of long-lived assets		-4,000
purchase (sale) of marketable securities		3,179,000		-1,855,000
income from marketable securities										-525,000		-310,000	-1,470,000	1,655,000	-909,000	-521,000
purchase of intangible assets								-250,000
effect of change in exchange rate on marketable securities, bank deposits and inter-company balances
loss (income) from marketable securities				1,572,000	760,000	247,000
effect of change in exchange rate on inter-company balances, marketable securities and bank deposits					-1,841,000	-1,728,000		-4,851,000	-586,000	-5,624,000	17,147,000	-28,918,000	84,658,000
increase in other receivables, income tax receivable, prepaid expenses and other						-3,462,000								8,402,000	-15,876,000	-21,483,000				19,612,000
increase in trade, income tax, accrued expenses, and other payables						483,957,000
(sale) purchase of marketable securities						-745,000
realized loss on sale of long-lived assets and marketable securities
decrease in other receivables, prepaid expenses and other
decrease in income tax receivables
proceeds from short-term bank deposits											174,158,000	51,345,000	-64,471,000	4,044,000	174,911,000	46,940,000
proceeds from long-term deposits and other assets											0	70,685,000									18,000
proceeds from (investment in) sale of long-lived assets
dividends paid
decrease in other receivables, income tax receivable, prepaid expenses and other								5,223,000	6,513,000	15,671,000
(income) income from marketable securities								28,000
sale of marketable securities								19,000
realized gain on sale of marketable securities
decrease in trade, income tax, accrued expenses, and other payables									10,826,000	-22,965,000	11,102,000	-17,408,000	-9,746,000		-3,962,000	-3,377,000
investment in the sale of plant, property & equipment
realized loss on sale of marketable securities and long-lived assets
proceeds from the sale of long-lived assets
realized gain on sale of marketable securities and long-lived assets											25,000	-7,000	257,000	-29,000	372,000	-247,000
decrease (increase) in other receivables, income tax receivable, prepaid expenses and other											9,472,000	52,479,000	-73,781,000					3,690,000
proceeds from the sale of property, plant and equipment
decrease (increase) in inventories												2,653,000
impairment of long-lived assets
proceeds from (investment in) long-term deposits and other assets														112,197,000
impairment for long-lived assets																		0	76,000	108,000
effect of change in exchange rate on inter-company balances and bank deposits														-4,661,000	39,486,000	22,078,000		-20,983,000	-13,135,000	4,101,000
(investment in) proceeds from other intangible assets
non-cash operating transactions:
sale of intangible asset
investment in long-term deposits and other assets																		-19,824,000	-138,289,000	-143,503,000
cash paid during the quarter for:
·
adjustments required to reconcile net income to net cash
provided by operating activities:
accrued severance pay and other long-term liabilities																					-210,000
(gain) loss on sale of long-lived assets
realized (gain) loss on sale of marketable securities
foreign exchange effect of bank deposits
decrease in long-term debt due to currency fluctuations
decrease (increase) in other long-term assets
decrease in trade payables
proceeds from (investment in) other assets
proceeds from (investment in) short-term bank deposits																	-54,684,000	112,510,000	47,590,000	90,754,000	18,045,000
proceeds from restricted bank deposits																					4,014,000
(investment in) proceeds from long-term deposits and other assets
proceeds from sale of long-lived assets																					28,000
proceeds from issuance of shares																					7,000
repayment of long-term debt
interest																					216,000
non-cash investing and financing transactions:
realized (gain) loss on sale of marketable securities and long-lived assets																		-8,512,000
decrease in trade, income tax and other payables and accrued expenses																		9,189,000	-17,311,000	-3,420,000
proceeds from (investment in) other intangible assets
proceeds from other assets
effect of change in exchange rate on inter-company balances
increase in trade, income tax and other payables and accrued expenses
(investment in) proceeds from other intangible assets and long-lived assets
change in deferred charges and other assets																					8,000
share-based compensation expense
loss on sale of long-lived assets																					22,000
effect of exchange differences on inter-company balances																					2,104,000
increase in long-term debt due to currency fluctuations																					814,000
decrease in long-term receivables, prepaid expenses and other
investment in other assets
excess tax benefits from share-based payment arrangements
purchase of property, plant and equipment on credit																					633,000
increase in long-term receivables, prepaid expenses and other
(investment in) proceeds from short-term bank deposits
proceeds from (investment in) restricted bank deposits
proceeds from sale of (investment in) marketable securities
repayment of short-term bank debt
proceeds from long-term debt and capital leases
(a) non-cash investing and financing transactions:
decrease in long-term receivables and other assets																					53,000
proceeds from short-term bank debt
(repayment of) proceeds from long-term debt																					-6,595,000
decrease (increase) in long-term receivables and other assets
(investment in) proceeds from restricted bank deposits
proceeds from sale (purchase) of marketable securities
(repayment of) proceeds from short-term bank debt
cash and cash equivalents at the beginning of the year
cash and cash equivalents at the end of the year
minority interest in earnings (losses) of a subsidiary
compensation in respect of options granted to non-employees
accrued severance pay
capital gain on sale of property, plant and equipment
currency fluctuation of long-term debt
tax benefit from exercise of options
increase in other accounts receivable and prepaid expenses
increase in income taxes payable
net cash provided (used in) by operating activities
acquisition of thames pharmacal company, inc.
purchase of product rights
long-term and other deposits
investment in restricted short-term bank deposits
proceeds from sale of property, plant and equipment
proceeds from exercise of options and issuance of shares of espp
proceeds from long-term debt
short-term bank credit and short-term loans
supplemental disclosure of cash flow transaction:
(a) acquisition of thames pharmacal company, inc.:
estimated fair value of assets acquired and liabilities assumed at the date of acquisition:
working capital deficiency
property, plant and equipment
intangible assets
goodwill
(b) non-cash investing and financing transactions:

We provide you with 20 years of cash flow statements for Taro Pharmaceutical Industries stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Taro Pharmaceutical Industries stock. Explore the full financial landscape of Taro Pharmaceutical Industries stock with our expertly curated income statements.

The information provided in this report about Taro Pharmaceutical Industries stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.